Targeted therapies suppress key pathways like RAS–RAF–MEK–ERK [63], and immune checkpoint inhibitors against PD‐1 and CTLA‐4 have shown efficacy in treating advanced melanoma but also other cancers [64, 65, 66, 67]. This evidence concerns the gene MAP2K7 and cancer.